Hi Afterlife,
You raise some excellent points - essentially it comes down to risk appetite in the investment.
My logic is to buy at the 7-10 cent range (opportunistically) and divest at the 18-20c cent range (allowing for margin as to where I think fair value resides), with the objective of yielding a 2.5x to 3x return, but acknowledge that it is early into the finalisation of the restructuring process.
I acknowledge that it is early on into the re-structuring process, that there is minimal volume and support for the equity, however I have balanced this with the relatively low cost the stock. If and when it is validated that the re-structuring process has been validated and cost benefits are being derived and once Tacera Pulse and Tacera RTLS are validated in the market with additional sales, then I would expect that the SP will gain traction.
I could easily see the price moving to 12-14c upon confirmation of the successful restructure - however at this point, the return would be 50% on the capital investment, versus 2.50x. Equally so, if the restructuring process fails or does not generate the envisioned returns or if the software platform does not meet market expectations then I could see the SP down to 5-6 cents. However, a 25% downside risk, versus a 2.5x potential upside risk seems like a fair investment.
I previously owned a business, that was a software/electronics business in the acute care hospital space, which had its head office in Perth and in 2007, we relocated our head office functions to the United States - which generated excellent returns (we also had offices in the UK, HK and Denmark).
So my summary is a buyer < 10c, holder at 11c to 17c and seller at 18c+ - all subject to change as the story unfolds.
- Forums
- ASX - By Stock
- AHC
- Azure Healthcare Revisited
AHC
austco healthcare limited
Add to My Watchlist
0.00%
!
30.0¢

Azure Healthcare Revisited, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
30.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $109.2M |
Open | High | Low | Value | Volume |
30.0¢ | 30.0¢ | 29.5¢ | $261.4K | 871.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 87168 | 29.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 87168 | 0.295 |
6 | 324280 | 0.290 |
1 | 3509 | 0.285 |
1 | 36000 | 0.280 |
1 | 15000 | 0.275 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 50000 | 1 |
0.305 | 16667 | 1 |
0.310 | 75511 | 4 |
0.315 | 170744 | 3 |
0.320 | 300726 | 4 |
Last trade - 15.33pm 04/07/2025 (20 minute delay) ? |
Featured News
AHC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online